AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.

Launch prices for prescription medicines approved by U.S. regulators in 2025 fell from the previous year, but remained high ...

A new medication could double survival time in patients with advanced pancreatic cancer, according to Phase III clinical ...

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...

UVA Health’s Dr. Matthew Reilley said the new drug is extending survival and reinvigorating the search for a cure.

Retatrutide, Eli Lilly’s new experimental drug, helped some participants lose up to 28 percent of their body weight in clinical trials. For millions of people who have struggled with weight loss, a ...

People are buying what they believe to be retatrutide from WhatsApp groups, Chinese labs and websites selling it “for ...

GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting "GLP-3s," claiming they are taking obesity medications to the next level. GLP-1 (glucagon-like peptide-1) ...

For millions of people who have struggled with weight loss, a new experimental drug from Eli Lilly may present the most promising option yet. Today, the pharmaceutical company announced the results ...